FN-1501
- Generic Name
- FN-1501
- Brand Names
- Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25N9O
- CAS Number
- 1429515-59-2
- Unique Ingredient Identifier
- 6MC966B505
- Background
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...
- Indication
Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...
- Associated Conditions
- Transplanted Organ Rejection
- Associated Therapies
- -
Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Secondary Acute Myeloid LeukemiaAdult Acute Myeloblastic Leukemia Without Maturation (M1)
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00045435
- Locations
- 🇺🇸
OHSU Cancer Institute, Portland, Oregon, United States
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
- Conditions
- Recurrent Adult Acute Lymphoblastic LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionBlastic PhaseChildhood Acute Lymphoblastic Leukemia in RemissionChildhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent DiseaseAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Chronic Phase of Disease
- Interventions
- Drug: CyclosporineDrug: DasatinibDrug: Fludarabine PhosphateDrug: Imatinib MesylateDrug: Mycophenolate MofetilDrug: NilotinibProcedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Peripheral Blood Stem Cell TransplantationBiological: Therapeutic Allogeneic LymphocytesRadiation: Total-Body Irradiation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00036738
- Locations
- 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States
Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT00041288
- Locations
- 🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
🇺🇸Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸University of Missouri Kansas City School of Medicine, Kansas City, Missouri, United States
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
- Conditions
- Adult Nasal Type Extranodal NK/T-cell LymphomaContiguous Stage II Small Lymphocytic LymphomaNoncontiguous Stage II Adult Diffuse Small Cleaved Cell LymphomaPeripheral T-cell LymphomaRecurrent Adult Acute Myeloid LeukemiaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Lymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00040846
- Locations
- 🇮🇹
University of Torino, Torino, Italy
🇺🇸Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States
🇺🇸Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00005941
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00006233
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00027547
- Locations
- 🇺🇸
Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
🇩🇪Universitaet Leipzig, Leipzig, Germany
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
- Conditions
- Recurrent Adult Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Childhood Non-Hodgkin LymphomaRefractory Childhood Hodgkin LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Hodgkin LymphomaRefractory Non-Hodgkin LymphomaT-Cell Chronic Lymphocytic LeukemiaT-Cell Prolymphocytic LeukemiaRecurrent Childhood Hodgkin Lymphoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationProcedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell TransplantationDrug: CarmustineDrug: CyclophosphamideDrug: CyclosporineDrug: CytarabineDrug: EtoposideDrug: Fludarabine PhosphateOther: Laboratory Biomarker AnalysisDrug: MelphalanDrug: Mycophenolate MofetilProcedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Peripheral Blood Stem Cell TransplantationBiological: Therapeutic Autologous LymphocytesRadiation: Total-Body Irradiation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 76
- Registration Number
- NCT00005803
- Locations
- 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸LDS Hospital, Salt Lake City, Utah, United States
🇺🇸VA Puget Sound Health Care System, Seattle, Washington, United States
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
- Conditions
- Adult Nasal Type Extranodal NK/T-cell LymphomaChildhood Burkitt LymphomaCutaneous B-cell Non-Hodgkin Lymphomade Novo Myelodysplastic SyndromesRecurrent Grade 1 Follicular LymphomaSmall Intestine LymphomaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Anaplastic Large Cell LymphomaChildhood Myelodysplastic Syndromes
- Interventions
- Drug: cyclophosphamideDrug: fludarabine phosphateDrug: tacrolimusDrug: mycophenolate mofetilGenetic: polymerase chain reactionGenetic: fluorescence in situ hybridizationGenetic: polymorphism analysisGenetic: gene expression analysisRadiation: total-body irradiationProcedure: allogeneic bone marrow transplantationProcedure: allogeneic hematopoietic stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT00049504
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.